![AllRock Biotech Targets Lung Diseases with Sanofi-Licensed Drug | [Disease 1] & [Disease 2] Treatment](https://medcitynews.com/wp-content/uploads/sites/7/2020/10/Jackie-Niam-lungs-getty-images-e1602021314401.jpg "AllRock Biotech Targets Lung Diseases with Sanofi-Licensed Drug | [Disease 1] & [Disease 2] Treatment")
AllRock Pharmaceuticals Launches Phase 2 Trial for Novel PAH Treatment, ROC-101, Challenging the status Quo
Pulmonary Arterial Hypertension (PAH) is a serious condition, and the landscape of treatment is evolving rapidly. AllRock Pharmaceuticals is poised to contribute substantially to this evolution with ROC-101,a first-in-class oral ROCK inhibitor,now entering a Phase 2 clinical trial. This advancement represents a perhaps groundbreaking approach to managing PAH and Pulmonary Hypertension with Interstitial Lung Disease (PH-ILD), offering hope for patients who haven’t found sufficient relief with existing therapies.
Understanding the Current PAH Treatment Landscape
Currently, treatments for PAH focus on managing symptoms and slowing disease progression. Recent advancements include innovative therapies like Winrevair, a subcutaneously injected fusion protein acquired by Merck through its $11.5 billion acquisition of Acceleron Pharma in 2021. Winrevair works by targeting a protein linked to the thickening of pulmonary vessels.It’s projected to be a major player in the PAH market.
However, the need for additional options remains. AllRock isn’t aiming to replace existing treatments like Winrevair, but rather to complement them, potentially providing a synergistic benefit for patients.
How ROC-101 Works: Targeting the ROCK Pathway
ROC-101 takes a different tack. It’s a pan-ROCK inhibitor, meaning it blocks the activity of Rho-associated coiled-coil containing protein kinases (ROCK). These enzymes play a crucial role in vasoconstriction and cellular proliferation within the pulmonary arteries. By inhibiting ROCK, ROC-101 aims to:
* Relax blood vessels: Leading to reduced pulmonary artery pressure.
* Prevent vessel thickening: Slowing the progression of the disease.
* Improve blood flow: Enhancing oxygenation and overall lung function.
This mechanism is supported by decades of research, including the use of fasudil, an older ROCK inhibitor approved in Japan and China for cerebral vasospasm. Off-label use and investigator-initiated studies have hinted at its efficacy in PAH, providing a strong rationale for ROC-101’s development.
The Phase 2 Trial: A Multi-pronged Approach
The upcoming 24-week Phase 2 trial is designed to rigorously evaluate ROC-101’s potential. It will enroll patients who continue to experience high pulmonary pressures despite being on current standard-of-care PAH medications. The trial features two key arms:
- Standard Drugs + ROC-101: Assessing the additive benefit of ROC-101.
- Standard of Care + Winrevair + ROC-101: Exploring a potential triple therapy approach.
Crucially, the trial also includes patients with PH-ILD, a challenging condition where high blood pressure in the lungs is linked to progressive lung disease. Currently, United Therapeutics’ Tyvasso is a standard treatment for PH-ILD, and Pulmovant (a Roivant Sciences subsidiary) is also pursuing an inhaled therapy. allrock believes ROC-101’s oral formulation offers a distinct advantage in this space.
Why ROC-101 Stands Out: Convenience and Validation
The oral formulation of ROC-101 is a meaningful advantage. Many existing PAH treatments require injections or inhalation, which can be burdensome for patients. A daily pill offers greater convenience and potentially improved adherence.
Furthermore, the underlying science behind ROC-101 is well-validated. The positive data from fasudil in Asia, though limited in Western markets, provides a strong foundation for the hypothesis that pan-ROCK inhibition can effectively treat PAH. As Alicia Levey of Versant notes, this “derisks” the development process.
A new Model for Biotech Innovation
AllRock Pharmaceuticals is part of a growing trend in biotech – the “hub-and-spoke” model. It was born from jucabio, a biopharmaceutical company that identifies promising drug assets and creates subsidiaries to accelerate thier development. This approach, also utilized by Roivant and BridgeBio Pharma, allows for efficient capital allocation and rapid progress.
In just 16 months, AllRock has moved ROC-101 from preclinical studies to Phase 2 readiness. This speed and efficiency are a testament to the team’s expertise, previously demonstrated at CinCor, where they successfully identified and advanced a promising asset leading to acquisition.
